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Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UKThe CFTR gene in addition to being extremely well from their laboratories. The CFTR gene is difficult to studystudied with respect to disease-associated mutations and
their effects on RNA processing has provided a valuable
tool for evaluation of the fundamental mechanism of tran-
scription and splicing. The size of the gene (190 kb) and the
extensive number of exons (27) renders global analysis of
mutations and splicing a time-consuming proposition. The
CFTR mRNA is present at low abundance and at tissue sites
that are often poorly accessible. However, the combined
efforts of the Cystic Fibrosis Genetic Analysis consortium
and other research teams have generated valuable tools and
reagents for these analyses. Many of the contributing
laboratories have also taken forward specific areas and
topics of interest and provided an in-depth analysis of the
mechanism of, for example, alternative splicing and CFTR
mRNA processing.
We include articles focused in five main methodological
areas: analysis of CFTR genomic DNA [1]; methods for
RNA extraction, cDNA preparation and analysis of CFTR
transcripts [2]; quantitative methods for the analysis of
CFTR transcripts/splicing variants [3]; non-PCR methods
for the analysis of CFTR transcripts [4]; and microarray
analysis in CF [5].
The articles published here include condensed versions
of various protocols available on the European Working
Group on CFTR Expression [6] and the latter should be
referred to by any researchers wishing to follow specific
techniques. We have been fortunate that many of the most
expert researchers in the field of CFTR transcript and
mutation analysis have been willing to share the techniques1569-1993/$ - see front matter D 2004 Published by Elsevier B.V. on behalf of E
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of its analysis. We hope that, by providing a resource of
robust methodologies, together with an account of the
potential problems and pitfalls, the hours of research time
already expended on this effort will make progress faster for
future researchers entering the field.References
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